Moreover, infusion of allogeneic bone marrow‐derived ABCB5+ (ATP‐binding cassette subfamily B member 5) dermal MSC, a subtype with increased potency to modulate underlying inflammatory response in a RDEB mouse model, is currently being tested in a phase 1/2 clinical trial in RDEB patients. Here, ABCB5 is linked to recessive dystrophic epidermolysis bullosa.